Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilar Interchangeability: NOR-SWITCH-Type Study Not Enough For US FDA

Nov 01 2016

• By Sue Sutter

Related Content

J&J Maintains Strategy For Biosimilar Remicade As Inflectra Nears

Oct 18 2016

Biosimilar Interchangeability Requirements Pushed At <em>Inflectra</em> Review

Feb 15 2016

Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?

Jul 22 2016

Biosimilar Guidance Development Timelines Criticized By Docs And Patients

Oct 21 2016

Biosimilars Switching Debate Escalates After Remicade and Remsima Match In Landmark Study

Oct 20 2016

Biosimilars: Sandoz Pegfilgrastim Review, Amgen Adalimumab Launch Extended To 2018

Oct 29 2016

Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action

Jul 15 2016

How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?

Oct 19 2016

Related Companies

Celltrion, Inc.

Johnson & Johnson

Novartis AG

Pfizer Inc.

Amgen, Inc.

AbbVie Inc.

Additional Topics

Biosimilars Drug Approval Standards Clinical Trials Regulation BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window